繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
CRISPR Therapeutics | 10-Q: Q3 2024 Earnings Report
CRISPR Therapeutics | 10-Q: Q3 2024 Earnings Report
CRISPR Therapeutics | 10-Q:2024財年三季報
牛牛AI助理已提取核心訊息
CRISPR Therapeutics, a leader in gene editing technology, has reported significant developments in its financial and operational activities as of September 30, 2024. Financially, the company has not generated revenue from product sales and does not anticipate doing so in the near future. However, it has recognized a small amount of grant revenue. The company's operating expenses have decreased, with research and development expenses dropping to $238.5 million from $292.2 million in the previous year. General and administrative expenses also saw a reduction. CRISPR Therapeutics has deferred $44.9 million in costs for the CASGEVY program under a collaboration with Vertex, compared to a deferral of $23.4 million in the previous year. The company's net loss has increased year-over-year, with a loss of...Show More
CRISPR Therapeutics, a leader in gene editing technology, has reported significant developments in its financial and operational activities as of September 30, 2024. Financially, the company has not generated revenue from product sales and does not anticipate doing so in the near future. However, it has recognized a small amount of grant revenue. The company's operating expenses have decreased, with research and development expenses dropping to $238.5 million from $292.2 million in the previous year. General and administrative expenses also saw a reduction. CRISPR Therapeutics has deferred $44.9 million in costs for the CASGEVY program under a collaboration with Vertex, compared to a deferral of $23.4 million in the previous year. The company's net loss has increased year-over-year, with a loss of $328.9 million compared to $242.9 million. In terms of business development, CRISPR Therapeutics has made strides with its flagship CRISPR/Cas9-based therapy, CASGEVY, which has been approved in multiple countries for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia. The company is also advancing several other gene-edited cell therapy programs for oncology and autoimmune diseases, as well as in vivo editing programs for cardiovascular disease. Looking ahead, CRISPR Therapeutics plans to continue its research and development efforts, with a focus on expanding clinical trials, advancing current programs, and identifying new product candidates. The company expects to incur increased expenses as it progresses with its development activities and prepares for potential commercialization of its product candidates.
作爲基因編輯技術領導者,crispr therapeutics已經報告了截至2024年9月30日的財務和運營活動方面的重大進展。從財務上看,該公司尚未從產品銷售中產生營業收入,並且不預計在不久的將來會產生。不過,公司已確認了一筆較小金額的補助收入。公司的營業費用有所下降,研發費用從去年的2.382億元下降到29220萬元。一般和行政費用也有所減少。crispr therapeutics已經推遲了4490萬元的CASGEVY項目成本,與去年的2340萬元推遲相比。公司的淨虧損同比增加,從24290萬元增至32890萬元。在業務發展方面,crispr therapeutics在旗艦CRISPR/C...展開全部
作爲基因編輯技術領導者,crispr therapeutics已經報告了截至2024年9月30日的財務和運營活動方面的重大進展。從財務上看,該公司尚未從產品銷售中產生營業收入,並且不預計在不久的將來會產生。不過,公司已確認了一筆較小金額的補助收入。公司的營業費用有所下降,研發費用從去年的2.382億元下降到29220萬元。一般和行政費用也有所減少。crispr therapeutics已經推遲了4490萬元的CASGEVY項目成本,與去年的2340萬元推遲相比。公司的淨虧損同比增加,從24290萬元增至32890萬元。在業務發展方面,crispr therapeutics在旗艦CRISPR/Cas9基因組編輯療法CASGEVY方面取得了進展,在多個國家獲得了批准,用於治療嚴重鐮狀細胞病和依賴輸血的β地中海貧血。該公司還在推進其他幾項用於腫瘤學和自身免疫疾病的基因編輯電芯療法項目,以及心血管疾病的體內編輯項目。展望未來,crispr therapeutics計劃繼續其研發工作,重點是擴大臨床試驗、推進當前項目和確定新的藥物候選者。公司預計隨着開發活動的進展和爲其產品候選者的潛在商業化做準備而將會發生增加的費用。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間